The global teicoplanin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Teicoplanin is an antibiotic used in the prevention as well as the treatment of serious infections caused by gram-positive bacteria, such as methicillin-resistant staphylococcus aureus and Enterococcus faecalis. Teicoplanin is a semi-synthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Amongst the variety of microbial flora present in human body, Staphylococcus aureus, a gram-positive bacterium, is most commonly found on the skin as well as nasal passages of humans. According to the United States Department of Health (USDoH), 20% of the global population is always colonized with Staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. Therefore, in order to treat such infectious disease and further use it as a preventive medicine, the demand for teicoplanin is likely to grow in the near future.
A full report of Global Teicoplanin Market is available at:https://orionmarketreports.com/global-teicoplanin-market/93915/
The increasing prevalence of staphylococcus aureus and enterococcus faecalis are also anticipated to boost the demand for teicoplanin. According to the Health Research Funding Organization, every year nearly 19,000 mortalities are registered globally due to Staph infection every year. According to Centre of Disease Control and Prevention (CDC), there were 13 cases in 4 states of the US, during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs. For instance, MRSA, a class of Staphylococcus aureus which is resistant to methicillin.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Sanofi S.A., and Cipla Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Teicoplanin Market Report by Segment
By Type
- 200 MG
- 400 MG
By Application
- Adults
- Children
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
